Casgevy List Price: $2.2 Million

Why $2.2 Million?

The price reflects several realities of gene therapy economics. Casgevy requires ex vivo cell collection, genetic editing in a laboratory, and reinfusion—a manufacturing process that is capital-intensive, labor-heavy, and carries significant quality-control overhead. Unlike a pill manufactured at scale, each dose is patient-specific. Vertex also priced the therapy against the lifetime cost of managing sickle cell disease (estimated at $1.5–$2 million per patient over a lifetime) and the value of eliminating transfusions, pain crises, and organ damage. The company positioned Casgevy as a one-time curative intervention, not a chronic maintenance drug.

Payer Response and Real-World Access

Despite the list price, most patients in the United States have not paid the full $2.2 million out-of-pocket. Medicare, Medicaid, and commercial insurers have negotiated confidential rebates and payment structures. Some states have used Medicaid managed-care carve-outs or specialty pharmacy arrangements to manage access. Vertex also established a patient-assistance program for uninsured and underinsured patients. The gap between list price and actual reimbursement is substantial—typical net prices to payers are reported to be 30–50% below list, though exact figures remain proprietary.

The Vertex-Casgevy Story

Vertex Pharmaceuticals is a Boston-based biotechnology company founded in 1989, originally known for cystic fibrosis therapies (Kalydeco, Trikafta). The company acquired the CRISPR gene-editing platform through its 2021 acquisition of CRISPR Therapeutics' development and commercialization rights for ex vivo CRISPR therapies in blood disorders. Casgevy is the first CRISPR therapy approved by the FDA for any indication in humans. Vertex holds the manufacturing and commercialization rights; CRISPR Therapeutics retains royalty rights on sales.

Market and Competitive Context

Casgevy faces competition from other curative or near-curative approaches: gene therapy (Bluebird Bio's Zynteglo, also for beta thalassemia, priced at $2.8 million list price but with limited U.S. availability), and hematopoietic stem cell transplantation (allogeneic bone marrow transplant, which carries its own morbidity and mortality risk). The $2.2 million price point has become a reference standard for ultra-rare, one-time curative therapies. It signals to the market that gene therapies for rare monogenic diseases will command premium pricing, even as payers push back on access and outcomes-based contracting becomes more common.

Regulatory and Reimbursement Precedent

The FDA's approval of Casgevy under a Biologics License Application (BLA) rather than a 510(k) reflects its novel mechanism and the rigorous clinical trial data required. Medicare's National Coverage Determination (NCD) for Casgevy, issued in 2024, covers the therapy for eligible patients with sickle cell disease or beta thalassemia, contingent on meeting specific clinical criteria and enrollment in a registry. This coverage decision legitimized the price but also created administrative burden for practices and infusion centers managing patient selection and insurance authorization.

The $2.2 million list price will likely anchor pricing for the next wave of curative CRISPR and gene-editing therapies entering the market. Payers are already developing frameworks for value-based pricing and outcomes guarantees—if a patient relapses or the therapy fails, rebates or price reductions may apply. For practice operators, Casgevy represents a new category of ultra-high-cost, low-volume specialty therapeutics that require dedicated reimbursement expertise and patient navigation support.